Alnylam Says DMC Recommends Continuation Of Phase 3 Trial Of Patisiran

(RTTNews) - Alnylam Pharmaceuticals, Inc. (ALNY) announced Monday that the Data Monitoring Committee or DMC for the Phase 3 APOLLO study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy recommended continuation of the trial without modification.

Earlier, the DMC has recommended discontinuation of the development of revusiran for the treatment of hereditary ATTR amyloidosis with cardiomyopathy.

The APOLLO study has completed enrollment of 225 patients at 44 sites in 19 countries, between December 2013 and January 2016.

ATTR amyloidosis is a progressively debilitating and often fatal disease caused by deposition of transthyretin in peripheral tissues.